OncoDaily Newsletter

Subscribe to our newsletter

Subscribe

FDA Grants Accelerated Approval to Neladalkib for ALK Positive Lung Cancer

How I Treat Pancreatic Cancer in 2026 – Virtual Summit

Prince Talal Honors 2026 King Hussein Cancer Research Award Winners on Behalf of King Abdullah II

Soon Thye Lim: NCCS, SGH and Suzhou Cancer Hospital Partner to Establish an International Hub for Cancer Care

Matthew Rabinowitz Receives the Oncology Vision Award at The Chemotherapy+ Foundation 2026 Innovation Gala

Cancer Care and the Hours Patients Cannot Get Back

EORTC AML21: Ten-Day Decitabine Shows Comparable Long-Term Survival to 3+7 Chemotherapy in Older AML Patients

Ernie Hudson: How the Ghostbusters Star Survived Prostate and Rectal Cancer

Immune Oncology

OncoDaily IO is the dedicated immuno-oncology platform of OncoDaily, focused on the rapidly evolving science and clinical practice of cancer immunotherapy. It covers the full spectrum of immuno-oncology, including immune checkpoint blockade, cellular therapies, therapeutic cancer vaccines, antibody-based strategies, oncolytic viruses, next-generation immunomodulatory approaches, tumor microenvironment, immune biomarkers, neoantigens, treatment response and resistance, and personalized immunotherapy. Through OncoDaily IO, readers can follow the latest clinical trials, pivotal studies, translational research, regulatory decisions, emerging therapies, major congress highlights, and interviews with leading international experts advancing cancer prevention, control, and treatment through immunotherapy.